Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12812113 | 0.86 | TDP1 (0.41) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL13627131 | 0.86 | LMNA (0.53) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL13267555 | 0.86 | LMNA (0.53) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8196834 | 0.82 | MEN1 (0.52) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL24762848 | 0.80 | LMNA (0.47) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL13137655 | 0.79 | ADRB2 (0.49) | LMNAHTTMEN1KMT2APOLB | |
| SCHEMBL8210156 | 0.77 | LMNA (0.67) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL1436122 | 0.77 | RAB9A (0.46) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL19965517 | 0.76 | LMNA (0.59) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8353840 | 0.76 | LMNA (0.59) | LMNATP53HTTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816408-B2 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090176993-A1 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176993-A1 | Calcium receptor active compounds | CASR, CALCR, CACNA1E | LMNA 4836/4885TP53 4031/4885HTT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.